DACS
EW icon

Dymon Asia Capital (Singapore)’s Edwards Lifesciences EW Stock Holding History

Dymon Asia Capital (Singapore)’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,088
Closed -$282K – 152
2020
Q4 		$282K Buy
+3,088
New +$256K 0.06% 101

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Dymon Asia Capital (Singapore)'s EW Position: Q1 2021 in Review

Dymon Asia Capital (Singapore) sold out of Edwards Lifesciences (EW) in Q1 2021, closing a stake of 3,088 shares — an estimated $282K sold.

Dymon Asia Capital (Singapore) first reported a position in EW in Q4 2020 and held it in 1 quarter. The position peaked at $282K in Q4 2020. 1,144 funds tracked by Wall St. Rank hold EW as of Q1 2021.

  • Dymon Asia Capital (Singapore) reported no remaining Edwards Lifesciences position as of Q1 2021 after selling out during the quarter.
  • Dymon Asia Capital (Singapore) sold 3,088 Edwards Lifesciences shares in Q1 2021, an estimated $282K.
  • Dymon Asia Capital (Singapore) first reported a position in Edwards Lifesciences in Q4 2020 and held it in 1 quarter.
  • Dymon Asia Capital (Singapore)'s Edwards Lifesciences position peaked at $282K in Q4 2020.
  • 1,144 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2021.

Based on Dymon Asia Capital (Singapore)'s 13F filing for Q1 2021, filed 14 May 2021.